Market revenue in 2024 | USD 3,916.0 million |
Market revenue in 2030 | USD 5,312.4 million |
Growth rate | 5.2% (CAGR from 2025 to 2030) |
Largest segment | Reagents product |
Fastest growing segment | Others Product |
Historical data covered | 2018 - 2023 |
Base year for estimation | 2024 |
Forecast period covered | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Instruments Product, Reagents Product, Others Product |
Key market players worldwide | Abbott Laboratories, Danaher Corp, BioMerieux SA, Roche Holding AG ADR, Bio-Rad Laboratories Inc, Agilent Technologies Inc, Becton Dickinson & Co, Hologic Inc, Illumina Inc, Grifols SA Ordinary Shares - Class A, Qiagen NV, Siemens Healthineers AG ADR, Sysmex Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to infectious disease molecular diagnostics market will help companies and investors design strategic landscapes.
Reagents product was the largest segment with a revenue share of 67.75% in 2024. Horizon Databook has segmented the Asia Pacific infectious disease molecular diagnostics market based on instruments product, reagents product, others product covering the revenue growth of each sub-segment from 2018 to 2030.
Increase in prohealth initiatives, adoption of better technologies, and rise in consumer awareness are driving growth in this region. In addition, rising prevalence of infectious diseases, increasing demand for cost-effective treatment, and growing target population are factors contributing to market growth.
Asia Pacific markets such as China, Australia, Korea, and Taiwan already have a healthcare reimbursement system that provides inclusive coverage for molecular diagnostic tests. Significantly high untapped opportunities in the form of unmet medical needs and increase in initiatives for scientific research are some primary growth drivers.
Moreover, improving healthcare regulatory scenario in the high-growth countries is expected to attract international players to invest and capitalize on the available opportunities. Positive changes, such as healthcare benefits being provided by governments, increased awareness among the population, and urge to avail high-end medical treatment are also expected to drive regional market growth.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific infectious disease molecular diagnostics market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific infectious disease molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account